Unigene Laboratories is a biopharmaceutical company, engaged in the research and development of peptides for medical purposes. The company was founded in 1980 and is located in New Jersey. The company's primary focus is on the development of calcitonin and related peptides for the treatment of osteoporosis. The company has licensed worldwide rights to its oral parathyroid hormone ("PTH") to GlaxoSmithKline.
| Property | Value |
| dbpedia-owl:Company/industry
| |
| dbpedia-owl:Organisation/foundationDate
|
- 1980-01-01 00:00:00 (xsd:date)
|
| dbpedia-owl:Organisation/keyPersonPosition
|
- James Gilligan, vice president, product development
- Warren Levy, president & CEO
|
| dbpedia-owl:Organisation/numberOfEmployees
| |
| dbpedia-owl:Organisation/type
| |
| dbpedia-owl:foundationDate
|
- 1980-01-01 00:00:00 (xsd:date)
|
| dbpedia-owl:industry
| |
| dbpedia-owl:keyPersonPosition
|
- James Gilligan, vice president, product development
- Warren Levy, president & CEO
|
| dbpedia-owl:numberOfEmployees
| |
| dbpedia-owl:type
| |
| dbpprop:abstract
|
- Unigene Laboratories is a biopharmaceutical company, engaged in the research and development of peptides for medical purposes. The company was founded in 1980 and is located in New Jersey. The company's primary focus is on the development of calcitonin and related peptides for the treatment of osteoporosis. The company has licensed worldwide rights to its oral parathyroid hormone ("PTH") to GlaxoSmithKline.
|
| dbpprop:companyName
| |
| dbpprop:companyType
| |
| dbpprop:foundation
| |
| dbpprop:hasPhotoCollection
| |
| dbpprop:homepage
| |
| dbpprop:industry
| |
| dbpprop:keyPeople
|
- Warren Levy, president & CEO
James Gilligan, vice president, product development
|
| dbpprop:numEmployees
| |
| dbpprop:reference
| |
| dbpprop:wikiPageUsesTemplate
| |
| dbpprop:wordnet_type
| |
| rdf:type
| |
| rdfs:comment
|
- Unigene Laboratories is a biopharmaceutical company, engaged in the research and development of peptides for medical purposes. The company was founded in 1980 and is located in New Jersey. The company's primary focus is on the development of calcitonin and related peptides for the treatment of osteoporosis. The company has licensed worldwide rights to its oral parathyroid hormone ("PTH") to GlaxoSmithKline.
|
| rdfs:label
| |
| owl:sameAs
| |
| skos:subject
| |
| foaf:homepage
| |
| foaf:name
| |
| foaf:page
| |
| is dbpprop:disambiguates
of | |
| is owl:sameAs
of | |